It is worth noting that this study included only results that were pathogenic or likely pathogenic, thus the true number of patients who could have benefited from genetic testing may be higher. Defining the clinical meaning of variants of unknown significance can be challenging in adult populations where testing of first-degree relatives may be more difficult. The authors acknowledge that the disorders defined in this cohort were pediatric-onset epilepsies; thus, we would expect most will now be diagnosed earlier in the setting of increased genetic testing in children. While the number of adults who will benefit from testing may decline in the future as a result, genetic testing has value now. Likewise, as the phenotypic spectrum of many genetic epilepsies expands, milder presentations that may not have prompted testing as children could still benefit from diagnosis as an adult.